Study of Motexafin Gadolinium and Docetaxel for Advanced Solid Tumors
The primary purpose of this study is to evaluate the safety, toxicities, and dosage for investigational drug Motexafin Gadolinium administered with docetaxel to patients with advanced solid tumors. Secondly, tumor response to the combined treatment will be evaluated.
Breast Neoplasms|Ovarian Neoplasms|Prostatic Neoplasms|Lung Neoplasms
DRUG: Motexafin Gadolinium Injection
Determine the Dose Limiting Toxicity at 3 weeks (1 cycle), and the Maximum Tolerated Dose at 24 weeks (6 cycles).
Frequency of tumor responses at weeks 6, 12 and 18.
The primary purpose of this study is to evaluate the safety, toxicities, and dosage for investigational drug Motexafin Gadolinium administered with docetaxel to patients with advanced solid tumors. Secondly, tumor response to the combined treatment will be evaluated.